Achieving incompatible transplantation through desensitization: Current perspectives and future directions

Immunotherapy

Volumn 7, Issue 4, 2015, Pages 377-398

  Jordan, Stanley C ^a,b   Choi, Jua ^a   Vo, Ashley ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

B cells; complement inhibition; desensitization; HLA; IL 6 receptor; immunotherapy; IVIg; kidney transplantation; plasma exchange; rituximab

Indexed keywords

ATR 107; BELATACEPT; BELIMUMAB; BORTEZOMIB; BRENTUXIMAB VEDOTIN; DACETUZUMAB; DARATUMUMAB; IBRUTINIB; IMMUNOGLOBULIN; LUCATUMUMAB; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OCRELIZUMAB; OFATUMUMAB; PF 05230900; RITUXIMAB; SECUKINUMAB; SILTUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG; VELTUZUMAB; HLA ANTIGEN;

ANTIBODY RESPONSE; B LYMPHOCYTE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DESENSITIZATION; HLA SYSTEM; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SENSITIZATION; TRANSPLANTATION; ANIMAL; GRAFT REJECTION; HISTOCOMPATIBILITY; ORGAN TRANSPLANTATION; PLASMA EXCHANGE; PROCEDURES; TRANSPLANTATION TOLERANCE; TRENDS;

ANIMALS; ANTIBODIES, MONOCLONAL; GRAFT REJECTION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; ORGAN TRANSPLANTATION; PLASMA EXCHANGE; RITUXIMAB; TRANSPLANTATION TOLERANCE;

EID: 84928806422     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.10     Document Type: Review

References (129)

1. El-Zoghby ZM, Stegall MD, Lager DJ et al. Identifying specific causes of kidney allograft loss. Am. J. Transplant. 9(3), 527-535 (2009).
2. Josephson MA. Monitoring and managing graft health in the kidney transplant recipient. Clin. J. Am. Soc. Nephrol. 6(7), 1774-1780 (2011).
3. Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat. Rev. Nephrol. 8(6), 348-357 (2012).
4. Evans RW, Manninen DL, Garrison LP et al. The quality of life of patients with end-stage renal disease. N. Engl. J. Med. 312(9), 553-559 (1985).
5. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 270(11), 1339-1343 (1993).
6. Organ Procurement and Transplantation Network (2009). http://optn. transplant. hrsa. gov
7. Bethesda M. US Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2, 326 (2013).
8. Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J. Am. Soc. Nephrol. 15(12), 3256-3262 (2004).
9. Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. Clin. J. Am. Soc. Nephrol. 6(4), 922-936 (2011).
10. Montgomery RA, Lonze BE, King KE et al. Desensitization in HLA-incompatible kidney recipients and survival. N. Engl. J. Med. 365(4), 318-326 (2011).
11. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359(3), 242-251 (2008).
12. Solez K, Colvin RB, Racusen LC et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am. J. Transplant. 7(3), 518-526 (2007).
13. Jordan SC, Reinsmoen N, Peng A et al. Advances in diagnosing and managing antibody-mediated rejection. Pediatr. Nephrol. 25(10), 2035-2045; quiz 2045-2038 (2010).
14. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J. Am. Soc. Nephrol. 18(4), 1046-1056 (2007).
15. Gloor J, Cosio F, Lager DJ, Stegall MD. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am. J. Transplant. 8(7), 1367-1373 (2008).
16. Lefaucheur C, Loupy A, Hill GS et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J. Am. Soc. Nephrol. 21(8), 1398-1406 (2010).
17. Jordan S, Reinsmoen N, Peng A et al. Advances in diagnosing and managing antibody-mediated rejection. Pediatr. Nephrol. 25(10), 2035-2045; quiz 2045-2048 (2010).
18. Vo AA, Petrozzino J, Yeung K et al. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation 95(6), 852-858 (2013).
19. Haas M, Sis B, Racusen LC et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am. J. Transplant. 14(2), 272-283 (2014).
20. Jeannet M, Pinn VW, Flax MH, Winn HJ, Russell PS. Humoral antibodies in renal allotransplantation in man. N. Engl. J. Med. 282(3), 111-117 (1970).
21. Levesque MC. Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin. Exp. Immunol. 157(2), 198-208 (2009).
22. Zachary AA, Eng HS. Desensitization: achieving immune detente. Tissue Antigens 77(1), 3-8 (2011).
23. Halloran PF, de Freitas DG, Einecke G et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am. J. Transplant. 10(10), 2223-2230 (2010).
24. Hidalgo LG, Campbell PM, Sis B et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am. J. Transplant. 9(11), 2532-2541 (2009).
25. Archdeacon P, Chan M, Neuland C et al. Summary of FDA antibody-mediated rejection workshop. Am. J. Transplant. 11(5), 896-906 (2011).
26. Smith RN, Colvin RB. Chronic alloantibody mediated rejection. Semin. Immunol. 24(2), 115-121 (2012).
27. Kouroukis TC, Baldassarre FG, Haynes AE, Imrie K, Reece DE, Cheung MC. Bortezomib in multiple myeloma: systematic review and clinical considerations. Curr. Oncol. 21(4), e573-603 (2014).
28. Wang X, Luo H, Chen H, Duguid W, Wu J. Role of proteasomes in T cell activation and proliferation. J. Immunol. 160(2), 788-801 (1998).
29. Baumjohann D, Preite S, Reboldi A et al. Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity 38(3), 596-605 (2013).
30. Tradtrantip L, Asavapanumas N, Verkman AS. Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase. Mol. Pharmacol. 83(6), 1268-1275 (2013).
31. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol. Rev. 237(1), 264-283 (2010).
32. Dörner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat. Rev. Rheumatol. 5(8), 433-441 (2009).
33. Rothstein TL. Grand challenges in B cell biology. Front. Immunol. 2, 2 (2011).
34. Barr TA, Shen P, Brown S et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J. Exp. Med. 209(5), 1001-1010 (2012).
35. Morsy DE, Sanyal R, Zaiss AK, Deo R, Muruve DA, Deans JP. Reduced T-dependent humoral immunity in CD20-deficient mice. J. Immunol. 191(6), 3112-3118 (2013).
36. Kuijpers TW, Bende RJ, Baars PA et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J. Clin. Invest. 120(1), 214-222 (2010).
37. Kohei N, Hirai T, Omoto K, Ishida H, Tanabe K. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am. J. Transplant. 12(2), 469-476 (2012).
38. Lynch RJ, Silva IA, Chen BJ, Punch JD, Cascalho M, Platt JL. Cryptic B cell response to renal transplantation. Am. J. Transplant. 13(7), 1713-1723 (2013).
39. Joosten I, Baas MC, Kamburova EG, van den Hoogen MW, Koenen HJ, Hilbrands LB. Anti-B cell therapy with rituximab as induction therapy in renal transplantation. Transpl. Immunol. 31(4), 207-209 (2014).
40. Vo AA, Choi J, Cisneros K et al. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation 98(3), 312-319 (2014).
41. Reinsmoen NL, Lai CH, Vo A, Jordan SC. Evolving paradigms for desensitization in managing broadly HLA sensitized transplant candidates. Discov. Med. 13(71), 267-273 (2012).
42. Hirohashi T, Chase CM, Della Pelle P et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am. J. Transplant. 12(2), 313-321 (2012).
43. Hidalgo LG, Sis B, Sellares J et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am. J. Transplant. 10(8), 1812-1822 (2010).
44. Jordan SC, Toyoda M, Vo AA. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev. Clin. Immunol. 7(3), 341-348 (2011).
45. Platt JL. Antibodies in transplantation. Discov. Med. 10(51), 125-133 (2010).
46. Jordan SC, Kahwaji J, Toyoda M, Vo A. B-cell immunotherapeutics: emerging roles in solid organ transplantation. Curr. Opin. Organ Transplant. 16(4), 416-424 (2011).
47. Hönger G, Hopfer H, Arnold ML, Spriewald BM, Schaub S, Amico P. Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation 92(1), 41-47 (2011).
48. Wahrmann M, Exner M, Schillinger M et al. Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Am. J. Transplant. 6(5 Pt 1), 1033-1041 (2006).
49. Mao Q, Terasaki PI, Cai J et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am. J. Transplant. 7(4), 864-871 (2007).
50. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 70(6), 887-895 (2000).
51. Vo AA, Peng A, Toyoda M et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 89(9), 1095-1102 (2010).
52. Reinsmoen NL, Lai CH, Vo A et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 86(6), 820-825 (2008).
53. Shapiro R. Reducing antibody levels in patients undergoing transplantation. N. Engl. J. Med. 359(3), 305-306 (2008).
54. Zachary AA, Lucas DP, Montgomery RA, Leffell MS. Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA. Transplantation 95(5), 701-704 (2013).
55. Loupy A, Suberbielle-Boissel C, Zuber J et al. Combined posttransplant prophylactic IVIg/anti-CD 20/ plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 89(11), 1403-1410 (2010).
56. Glotz D, Antoine C, Julia P et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am. J. Transplant. 2(8), 758-760 (2002).
57. Shehata N, Palda VA, Meyer RM et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus Med. Rev. 24(Suppl. 1), S7-S27 (2010).
58. Marfo K, Ling M, Bao Y et al. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation 94(4), 345-351 (2012).
59. Lobashevsky AL, Higgins NG, Rosner KM, Mujtaba MA, Goggins WC, Taber TE. Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab. Transplantation 96(2), 182-190 (2013).
60. Orandi BJ, Garonzik-Wang JM, Massie AB et al. Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am. J. Transplant. 14(7), 1573-1580 (2014).
61. Fan X, Ang A, Pollock-Barziv SM et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat. Med. 10(11), 1227-1233 (2004).
62. Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 86(12), 1754-1761 (2008).
63. Yang KS, Jeon H, Park Y et al. Use of bortezomib as anti-humoral therapy in kidney transplantation. J. Korean Med. Sci. 29(5), 648-651 (2014).
64. Ejaz NS, Shields AR, Alloway RR et al. Randomized controlled pilot study of B cell-targeted induction therapy in HLA sensitized kidney transplant recipients. Am. J. Transplant. 13(12), 3142-3154 (2013).
65. Nandakumar KS, Johansson BP, Björck L, Holmdahl R. Blocking of experimental arthritis by cleavage of IgG antibodies in vivo. Arthritis Rheum. 56(10), 3253-3260 (2007).
66. Johansson BP, Shannon O, Björck L. IdeS: a bacterial proteolytic enzyme with therapeutic potential. PLoS ONE 3(2), e1692 (2008).
67. Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 88(1), 1-6 (2009).
68. Jordan SC, Toyoda M, Kahwaji J, Vo AA. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am. J. Transplant. 11(2), 196-202 (2011).
69. Jordan SC, Vo AA. Desensitization offers hope to highly HLA-sensitized patients for a longer life expectancy after incompatible kidney transplant. Am. J. Kidney Dis. 59(6), 758-760 (2012).
70. Gandhi PK, Gentry WM, Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 32(10), 902-909 (2012).
71. Schürmann D, Herzog E, Raquet E et al. C1-esteraseinhibitor treatment: preclinical safety aspects on the potential prothrombotic risk. Thromb. Haemost. 112(5) (2014).
72. Orandi BJ, Zachary AA, Dagher NN et al. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation 98(8), 857-663 (2014).
73. Koon HB, Junghans RP. Anti-CD30 antibody-based therapy. Curr. Opin. Oncol. 12(6), 588-593 (2000).
74. Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC. Future agents and treatment directions in multiple myeloma. Expert Rev. Hematol. 7(1), 127-141 (2014).
75. Guthoff M, Schmid-Horch B, Weisel KC, Häring HU, Königsrainer A, Heyne N. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transpl. Immunol. 26(4), 171-175 (2012).
76. Shanafelt T, Lanasa MC, Call TG et al. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer 119(21), 3788-3796 (2013).
77. Basu B. Ofatumumab for rituximab-resistant nephrotic syndrome. N. Engl. J. Med. 370(13), 1268-1270 (2014).
78. Reichert JM. Antibodies to watch in 2014. MAbs 6(1), 5-14 (2014).
79. Lee HZ, Miller BW, Kwitkowski VE et al. U. S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia. Clin. Cancer Res. 20(15), 3902-3907 (2014).
80. Antoniu S. Epratuzumab for systemic lupus erythematosus. Expert Opin. Biol. Ther. 14(7), 1045-1047 (2014).
81. Relan M, Vishwanath S, Shen L, Ambrus JL. Update on the use of biologics in lupus. Curr. Pharm. Biotechnol. 15(6), 516-520 (2014).
82. Strand V, Petri M, Kalunian K et al. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford) 53(3), 502-511 (2014).
83. de Weers M, Tai YT, van der Veer MS et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186(3), 1840-1848 (2011).
84. Khagi Y, Mark TM. Potential role of daratumumab in the treatment of multiple myeloma. Onco. Targets Ther. 7, 1095-1100 (2014).
85. Advani RH, Buggy JJ, Sharman JP et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31(1), 88-94 (2013).
86. Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J. Clin. Oncol. 31(1), 128-130 (2013).
87. Burger JA, Keating MJ, Wierda WG et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, Phase 2 study. Lancet Oncol. 15( 10), 1090-1099 (2014).
88. Honigberg LA, Smith AM, Sirisawad M et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107(29), 13075-13080 (2010).
89. Shah N, Hutchinson C, Rule S. Ibrutinib for the treatment of mantle cell lymphoma. Expert Rev. Hematol. 7(5), 521-531 (2014).
90. O'Brien S, Furman RR, Coutre SE et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, Phase 1b/2 trial. Lancet Oncol. 15(1), 48-58 (2014).
91. Ansell SM, Horwitz SM, Engert A et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J. Clin. Oncol. 25(19), 2764-2769 (2007).
92. Younes A, Gopal AK, Smith SE et al. Results of a pivotal Phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol. 30(18), 2183-2189 (2012).
93. de Claro RA, McGinn K, Kwitkowski V et al. U. S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin. Cancer Res. 18(21), 5845-5849 (2012).
94. Vaklavas C, Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther. Adv. Hematol. 3(4), 209-225 (2012).
95. Rostaing L, Vincenti F, Grinyó J et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am. J. Transplant. 13(11), 2875-2883 (2013).
96. Hassan SB, SØrensen JF, Olsen BN, Pedersen AE. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol. Immunotoxicol. 36(2), 96-104 (2014).
97. Byrd JC, Kipps TJ, Flinn IW et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk. Lymphoma 53(11), 2136-2142 (2012).
98. Banham G, Prezzi D, Harford S et al. Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection. Transplantation 96(4), 413-420 (2013).
99. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 4(11), 2860-2867 (1990).
100. Jones SA, Fraser DJ, Fielding CA, Jones GW. Interleukin-6 in renal disease and therapy. Nephrol. Dial. Transplant. pii: gfu233 (2014).
101. Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol. Res. 2(4), 288-294 (2014).
102. van Rhee F, Wong RS, Munshi N et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 15(9), 966-974 (2014).
103. Hua F, Comer GM, Stockert L et al. Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a Phase I, first-in-human study. J. Clin. Pharmacol. 54(1), 14-22 (2014).
104. Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis-results of two Phase 3 trials. N. Engl. J. Med. 371(4), 326-338 (2014).
105. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10(5), 301-316 (2010).
106. Emery P, Rigby W, Tak PP et al. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab Phase III program. PLoS ONE 9(2), e87379 (2014).
107. Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk. Lymphoma 51(5), 747-755 (2010).
108. Mei HE, Schmidt S, Dörner T. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res. Ther. 14(Suppl. 5), S1 (2012).
109. Dolgin E. Cancer's true breakthroughs. Nat. Med. 19(6), 660-663 (2013).
110. Wang ML, Rule S, Martin P et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369(6), 507-516 (2013).
111. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 118(16), 4313-4320 (2011).
112. Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int. Rev. Immunol. 31(2), 119-132 (2012).
113. Agrawal B, Reddish M, Longenecker BM. CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors. J. Immunol. 157(8), 3229-3234 (1996).
114. Grenzi PC, Campos É, Tedesco-Silva H et al. Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy. Transpl. Immunol. 29(1-4), 34-38 (2013).
115. Gupta G, Womer KL. Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation. Drug Des. Devel. Ther. 4, 375-382 (2010).
116. Wu G, Kim I, Chai N-n et al. CTLA4Ig Differentially suppresses de novo and recall alloantibody responses in a mouse model of HLA. A2 allosensitization. Presented at: World Transplant Congress 2014 (Poster Presentation). San Francisco, CA, USA, 26-31 July 2014.
117. Korniluk A, Kemona H, Dymicka-Piekarska V. Multifunctional CD40L: pro-and anti-neoplastic activity. Tumour Biol. 35(10), 9447-9457 (2014).
118. Clatworthy MR. B-cell regulation and its application to transplantation. Transpl. Int. 27(2), 117-128 (2014).
119. Zhao X, Boenisch O, Yeung M et al. Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance. Am. J. Transplant. 12(1), 90-101 (2012).
120. Booth AJ, Grabauskiene S, Wood SC, Lu G, Burrell BE, Bishop DK. IL-6 promotes cardiac graft rejection mediated by CD4+ cells. J. Immunol. 187(11), 5764-5771 (2011).
121. Fogal B, Yi T, Wang C et al. Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells. J. Immunol. 187(12), 6268-6280 (2011).
122. Noguchi D, Wakita D, Ohkuri T et al. Blockade of IL-6-signaling inhibits the pathogenesis of CD4+ T cell-mediated lethal graft-versus-host reaction against minor histocompatibility antigen. Immunol Lett. 136(2), 146-155 (2011).
123. Kim I, Wu G, Chai NN, Klein AS, Jordan S. Anti-interleukin 6 receptor antibodies attenuate antibody recall responses in a mouse model of allosensitization. Transplantation doi:10. 1097/TP. 0000000000000437 (2014) (Epub ahead of print).
124. Tanaka T, Kishimoto T. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int. J. Biol. Sci. 8(9), 1227-1236 (2012).
125. Muhammad K, Roll P, Seibold T et al. Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells. Ann. Rheum. Dis. 70(8), 1507-1510 (2011).
126. Illei GG, Shirota Y, Yarboro CH et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label Phase I dosage-escalation study. Arthritis Rheum. 62(2), 542-552 (2010).
127. Vo A, Choi J, Cisneros K et al. A Phase I/II Trial of tocilizumab (anti-Il-6 receptor) + intravenous immunoglobulin (IVIG) for desensitization (DES) in difficult to DES patients. Presented at: World Transplant Congress 2014. San Francisco, CA, USA, 26-31 July 2014.
128. Sullivan JA, Adams AB, Burlingham WJ. The emerging role of TH17 cells in organ transplantation. Transplantation 97(5), 483-489 (2014).
129. Nouël A, Simon Q, Jamin C, Pers JO, Hillion S. Regulatory B cells: an exciting target for future therapeutics in transplantation. Front. Immunol. 5, 11 (2014).